Evidence map›Paper›PMID 18682919›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2009

Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.

Peter Heusler, Liesbeth Bruins Slot, Isabelle Rauly-Lestienne, Christiane Palmier, Stéphanie Tardif, Amélie Tourette, Marie-Christine Ailhaud, Didier Cussac

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Peter HeuslerDepartment of Cellular and Molecular Biology, Centre de Recherche Pierre Fabre, 17, avenue Jean Moulin, F-81106, Castres Cedex, France. peter.heusler@pierre-fabre.com.
Liesbeth Bruins Slot
Isabelle Rauly-Lestienne
Christiane Palmier
Stéphanie Tardif
Amélie Tourette
Marie-Christine Ailhaud
Didier Cussac
Pierre Fabre (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Agonist activity at recombinant human dopamine D4.4 receptors was compared in stably transfected CHO cells using two functional readouts: G protein activation by [35S]GTPgammaS binding and phosphorylation of extracellular signal-regulated kinase 1/2 (pERK1/2). Results with a large series of agonists reveal markedly higher relative agonist efficacy in the pERK1/2 assay compared with [35S]GTPgammaS binding, while potencies were generally higher in the latter readout. Whereas efficacies were highly correlated when comparing both tests, potencies determined using the pERK1/2 assay were neither correlated with those for G protein activation nor with binding affinities. In order to examine if these differences may be attributable to distinct assay conditions (5 min incubation for pERK1/2 compared with binding equilibrium conditions for [35S]GTPgammaS), selected compounds were tested in a modified short-duration [35S]GTPgammaS binding assay. In these experiments, potencies were generally reduced; however, compounds exhibiting comparably high potency in the pERK1/2 assay were not affected by this duration-dependent potency shift. We conclude that assay parameters such as signal amplification and incubation time have to be considered with respect to the appropriate choice of experimental approaches that best reflect agonist activity at dopamine D4 receptors in vivo.

Indexed as

AnimalsAntipsychotic AgentsBinding, CompetitiveCHO CellsCricetinaeCricetulusDopamineDopamine AgonistsDopamine AntagonistsDose-Response Relationship, DrugEnzyme ActivationEpinephrineGTP-Binding ProteinsGuanosine 5'-O-(3-Thiotriphosphate)HumansMitogen-Activated Protein Kinase 1Antipsychotic AgentsDopamineDopamine AgonistsDopamine AntagonistsEpinephrineGTP-Binding ProteinsGuanosine 5'-O-(3-Thiotriphosphate)Mitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NorepinephrineReceptors, Dopamine D4

Identifiers

PMID18682919
OpenAlexW2049590247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.